[144] Jazz Pharmaceuticals, Inc. SEC Filing
Jazz Pharmaceuticals (JAZZ) filed a Rule 144 notice reporting a proposed sale of 3,731 common shares with an aggregate market value of $417,872. The sale is scheduled on NASDAQ for 08/08/2025 and lists E*TRADE Financial Corporation as broker.
The filing shows these shares were acquired on 08/07/2025 through restricted stock vesting from the issuer and were paid as compensation. The filing also reports 60,658,809 shares outstanding and notes "Nothing to Report" for securities sold in the past three months.
Jazz Pharmaceuticals (JAZZ) ha depositato un avviso ai sensi della Rule 144 che segnala una proposta di vendita di 3.731 azioni ordinarie per un valore di mercato complessivo di $417,872. La vendita 猫 prevista sul NASDAQ per il 08/08/2025 e indica come broker la E*TRADE Financial Corporation.
Il documento mostra che queste azioni sono state acquisite il 08/07/2025 tramite vesting di azioni soggette a restrizioni dall'emittente e sono state corrisposte come compenso. Il deposito riporta inoltre 60,658,809 azioni in circolazione e annota "Nothing to Report" riguardo a titoli venduti negli ultimi tre mesi.
Jazz Pharmaceuticals (JAZZ) present贸 un aviso conforme a la Rule 144 informando una propuesta de venta de 3.731 acciones ordinarias por un valor de mercado agregado de $417,872. La venta est谩 programada en el NASDAQ para el 08/08/2025 y se帽ala a E*TRADE Financial Corporation como corredor.
El expediente indica que estas acciones fueron adquiridas el 08/07/2025 mediante vesting de acciones restringidas por parte del emisor y se pagaron como 肠辞尘辫别苍蝉补肠颈贸苍. Tambi茅n informa 60,658,809 acciones en circulaci贸n y anota "Nothing to Report" respecto a valores vendidos en los 煤ltimos tres meses.
Jazz Pharmaceuticals (JAZZ)臧� Rule 144 韱奠靹滊ゼ 鞝滌稖頃橃棳 齑� 鞁滉皜臧� $417,872鞚� 3,731 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 氤搓碃頄堨姷雼堧嫟. 毵り皝鞚� NASDAQ鞐愳劀 08/08/2025鞐� 鞓堨爼霅橃柎 鞛堨溂氅� 欷戧皽鞚胳溂搿� E*TRADE Financial Corporation鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
鞝滌稖 靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 08/07/2025鞐� 氚滍枆靷攵�韯办潣 鞝滍暅欤检嫕鞚� 氩犾姢韺�鞚� 韱淀暣 旆摑霅橃棃瓿� 氤挫儊鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 霕愴暅 60,658,809欤检潣 氚滍枆 欤检嫕 靾橂ゼ 氤搓碃頃橂┌, 斓滉芳 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃挫劀電� "Nothing to Report"搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Jazz Pharmaceuticals (JAZZ) a d茅pos茅 un avis en vertu de la Rule 144 signalant une proposition de vente de 3 731 actions ordinaires pour une valeur marchande totale de $417,872. La vente est pr茅vue sur le NASDAQ le 08/08/2025 et indique E*TRADE Financial Corporation comme courtier.
Le dossier pr茅cise que ces actions ont 茅t茅 acquises le 08/07/2025 par vesting d'actions restreintes de l'茅metteur et ont 茅t茅 vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅p么t fait 茅galement 茅tat de 60,658,809 actions en circulation et note "Nothing to Report" pour les titres vendus au cours des trois derniers mois.
Jazz Pharmaceuticals (JAZZ) hat eine Mitteilung nach Rule 144 eingereicht, die einen geplanten Verkauf von 3.731 Stammaktien mit einem Gesamtmarktwert von $417,872 meldet. Der Verkauf ist f眉r den 08/08/2025 an der NASDAQ vorgesehen und nennt E*TRADE Financial Corporation als Broker.
Die Einreichung gibt an, dass diese Aktien am 08/07/2025 durch Restricted-Stock-Vesting vom Emittenten erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt wurden. Weiterhin werden 60,658,809 ausstehende Aktien gemeldet und f眉r in den letzten drei Monaten verkaufte Wertpapiere wird "Nothing to Report" vermerkt.
- None.
- None.
Insights
TL;DR: Routine Rule 144 notice for a small insider sale from vested restricted stock; unlikely to be market-moving.
The filing documents a proposed sale of 3,731 common shares valued at $417,872 to be executed on NASDAQ. The shares were acquired one day earlier through restricted stock vesting and classified as compensation. As a securities analyst, this reads as a standard insider reporting requirement under Rule 144 rather than an indication of new corporate developments; the filing contains no disclosures of material nonpublic information.
TL;DR: Compliance-focused disclosure showing internal compensation vesting and a required resale notice; governance risk appears limited.
The notice confirms the seller represents there is no undisclosed material adverse information and references trading-plan language. The transaction arises from restricted stock vesting and the signature attestation is standard for Form 144 filings. From a governance perspective, the filing documents routine insider activity and the required compliance statements.
Jazz Pharmaceuticals (JAZZ) ha depositato un avviso ai sensi della Rule 144 che segnala una proposta di vendita di 3.731 azioni ordinarie per un valore di mercato complessivo di $417,872. La vendita 猫 prevista sul NASDAQ per il 08/08/2025 e indica come broker la E*TRADE Financial Corporation.
Il documento mostra che queste azioni sono state acquisite il 08/07/2025 tramite vesting di azioni soggette a restrizioni dall'emittente e sono state corrisposte come compenso. Il deposito riporta inoltre 60,658,809 azioni in circolazione e annota "Nothing to Report" riguardo a titoli venduti negli ultimi tre mesi.
Jazz Pharmaceuticals (JAZZ) present贸 un aviso conforme a la Rule 144 informando una propuesta de venta de 3.731 acciones ordinarias por un valor de mercado agregado de $417,872. La venta est谩 programada en el NASDAQ para el 08/08/2025 y se帽ala a E*TRADE Financial Corporation como corredor.
El expediente indica que estas acciones fueron adquiridas el 08/07/2025 mediante vesting de acciones restringidas por parte del emisor y se pagaron como 肠辞尘辫别苍蝉补肠颈贸苍. Tambi茅n informa 60,658,809 acciones en circulaci贸n y anota "Nothing to Report" respecto a valores vendidos en los 煤ltimos tres meses.
Jazz Pharmaceuticals (JAZZ)臧� Rule 144 韱奠靹滊ゼ 鞝滌稖頃橃棳 齑� 鞁滉皜臧� $417,872鞚� 3,731 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 氤搓碃頄堨姷雼堧嫟. 毵り皝鞚� NASDAQ鞐愳劀 08/08/2025鞐� 鞓堨爼霅橃柎 鞛堨溂氅� 欷戧皽鞚胳溂搿� E*TRADE Financial Corporation鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
鞝滌稖 靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 08/07/2025鞐� 氚滍枆靷攵�韯办潣 鞝滍暅欤检嫕鞚� 氩犾姢韺�鞚� 韱淀暣 旆摑霅橃棃瓿� 氤挫儊鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 霕愴暅 60,658,809欤检潣 氚滍枆 欤检嫕 靾橂ゼ 氤搓碃頃橂┌, 斓滉芳 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃挫劀電� "Nothing to Report"搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Jazz Pharmaceuticals (JAZZ) a d茅pos茅 un avis en vertu de la Rule 144 signalant une proposition de vente de 3 731 actions ordinaires pour une valeur marchande totale de $417,872. La vente est pr茅vue sur le NASDAQ le 08/08/2025 et indique E*TRADE Financial Corporation comme courtier.
Le dossier pr茅cise que ces actions ont 茅t茅 acquises le 08/07/2025 par vesting d'actions restreintes de l'茅metteur et ont 茅t茅 vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅p么t fait 茅galement 茅tat de 60,658,809 actions en circulation et note "Nothing to Report" pour les titres vendus au cours des trois derniers mois.
Jazz Pharmaceuticals (JAZZ) hat eine Mitteilung nach Rule 144 eingereicht, die einen geplanten Verkauf von 3.731 Stammaktien mit einem Gesamtmarktwert von $417,872 meldet. Der Verkauf ist f眉r den 08/08/2025 an der NASDAQ vorgesehen und nennt E*TRADE Financial Corporation als Broker.
Die Einreichung gibt an, dass diese Aktien am 08/07/2025 durch Restricted-Stock-Vesting vom Emittenten erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt wurden. Weiterhin werden 60,658,809 ausstehende Aktien gemeldet und f眉r in den letzten drei Monaten verkaufte Wertpapiere wird "Nothing to Report" vermerkt.
FAQ
What does the Form 144 for Jazz Pharmaceuticals (JAZZ) report?
How were the securities being sold acquired?
Who is the broker listed on the Form 144?
How many shares outstanding does the filing list for the issuer?
Were any securities sold by this person in the past three months?
